Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.449
Sell
RSI(14)
44.509
Neutral
STOCH(KDJ)(9,3,3)
25.597
Neutral
ATR(14)
1.147
Low Volatility
CCI(14)
-111.755
Sell
Williams %R
80.682
Oversold
TRIX(12,20)
-0.037
Sell
StochRSI(14)
50.727
Buy
Search
GSK plc
GSKAdd to Watchlist
50.745USD
-0.015-0.03%
Close 07-23 16:00（ET）Quotes delayed by 15 min
102.88BMarket Cap
13.08P/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-0.03%
5 Days
-3.84%
1 Month
-2.54%
6 Months
+3.25%
Year to Date
+3.48%
1 Year
+33.43%
Key Figures
50.060Open
50.870High
4.12MVolume
13.08P/E TTM
9.88P/E Dynamic
--Dividend TTM
0.20%Turnover Ratio
50.760Prev. Close
49.890Low
139.50MTurnover
31.27P/E Static
4.36P/B
0.00%Div Yield TTM
10.56%ROA
61.69552wk High
0.74Volume Ratio
3.29BNet Profit
2.03BShares
3.8800EPS TTM
0.38Beta
37.35%ROE
35.45052wk Low
1.93%Amplitude
75.54%Gross Margin
102.88BMarket Cap
-0.59Reward/Risk
1.09%Risk Rate
TradingKey Stock Score of GSK plc
Currency: USD Updated: 2026-07-23Key Insights
GSK plc's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 61 out of 155 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 54.01.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
GSK plc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
GSK plc Highlights
StrengthsRisks
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 43.02B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 96.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 96.66%.
Undervalued
The company’s latest PE is 13.08, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 393.46M shares, decreasing 5.63% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 8.04M shares of this stock.
Analyst Rating
Based on
10
analysts
Buy
Current Rating
54.011
Target Price
+6.36%
Upside Space
Earnings Forecast
Analyst Rating
Based on
10
analysts
Buy
Current Rating
54.011
Target Price
+6.36%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
160
Total
6
Median
9
Average
Company name
Ratings
Analysts
GSK plc
GSK
10
Biogen Inc
BIIB
38
Amgen Inc
AMGN
37
Eli Lilly and Co
LLY
34
AbbVie Inc
ABBV
33
Pfizer Inc
PFE
32
1
2
3
...
32
Indicators
Moving Average
Indicators
Value
Direction
MA5
50.816
Sell
MA10
51.462
Sell
MA20
52.030
Sell
MA50
51.479
Sell
MA100
53.059
Sell
MA200
51.340
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
GSK plc Info
GSK plc is a biopharma company. The Company’s segments include Commercial Operations and Research and Development. Its portfolio and pipeline are focused on developing medicines and vaccines in four core therapeutic areas, which are the areas of human health it focuses on to prevent and treat disease: respiratory, immunology and inflammation; oncology; human immunodeficiency virus (HIV), and infectious diseases. Its specialty medicines prevent and treat diseases, from HIV to respiratory diseases, immune-mediated conditions like lupus, and cancer. Its vaccine portfolio includes over 20 vaccines to protect people from diseases and infections throughout their lives. General medicines include inhaled medicines for asthma and COPD to antibiotics. It develops and commercializes preclinical antibody-drug conjugate for Metastatic castration-resistant prostate cancer. Its portfolio also includes Efimosfermin, a fibroblast growth factor 21 (FGF21) analog therapeutic in clinical development.
Ticker SymbolGSK
CompanyGSK plc
CEOWaterhouse (Deborah)
Websitehttps://www.gsk.com/
Shareholders
Related Instruments
+1.95%
+1.46%
-0.85%
+1.43%
+2.37%
+2.01%
+1.49%
+0.38%
0.00%
+0.71%
+1.27%
+0.15%
-0.94%
+1.31%
0.00%
+0.11%
+8.61%
-0.21%
+2.45%Popular Instruments
FAQs
What is the current price of GSK plc (GSK)?
The current price of GSK plc (GSK) is 50.74.
What is the symbol of GSK plc?
The ticker symbol of GSK plc is GSK.
What is the 52-week high of GSK plc?
The 52-week high of GSK plc is 61.70.
What is the 52-week low of GSK plc?
The 52-week low of GSK plc is 35.45.
What is the market capitalization of GSK plc?
The market capitalization of GSK plc is 102.88B.
Is GSK plc (GSK) currently rated as Buy, Hold, or Sell?
According to analysts, GSK plc (GSK) has an overall rating of Buy, with a price target of 54.01.
What is the Earnings Per Share (EPS TTM) of GSK plc (GSK)?
The Earnings Per Share (EPS TTM) of GSK plc (GSK) is 3.72.